Podcasts about Amgen

Melissa sits down with Tricia Totten aka @flexingaftercancer, 56 year-old breast cancer thriver, bone health and fitness advocate to share her first hand experience about how to keep your bones strong and healthy after a breast cancer diagnosis and menopause.  Tricia is such a great example of being super proactive and advocating for your bone health! Thank you to Amgen for making this episode possible by supporting this special #beautifultothebone series.

Cancer is one therapeutic area where patients cannot wait the conventional 10 or 12 years for a new therapy. For these patients, time is of the essence, and improved access to faster clinical trials can be the difference between receiving a new life-saving medicine and it being too late. In this episode, we talk to David Raben, vice president of Global Development Oncology at Amgen, about the next generation of oncology trial design and execution. To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.   Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.

The covid pandemic has brought into sharp focus the benefits as well as the challenges posed by the global supply chain related to the development of innovative new drugs. Paul Neureiter is the Executive Director for International Government Affairs & Trade Policy at Amgen. Before taking a role in ‘big pharma', Paul was the Senior Director for China Affairs for the Office of the U.S. Trade Representative (USTR) and was part of the U.S. Foreign Service from 1987 to 2001. In this podcast we discuss how price controls for therapies can be a Faustian bargain, creating short term gain for long term losses, where patients are ultimately those who suffer the most. We also touch on the WTO and US Trade's decision to use TRIPs waivers to potentially pry open intellectual property rights for the mRNA technologies, and the broader implications of those decisions. As well, we highlight how the EU's approach to viewing biopharmaceutical innovation as a cost, and not as an investment, has had a demonstrably negative impact on their development of new, small, and innovative biotechnology firms like those driving US innovation and helping meet unmet medical needs for patients. Finally, we touch upon how Build Back Better can cause similar damage to the US innovation ecosystem as price controls have in the EU, and how China is quickly gaining on American biopharma innovation, and what that portends if the wrong political decisions are taken in the US Congress.See omnystudio.com/listener for privacy information.

Gastrointestinal cancer experts Dr. Aparna Parikh and Dr. Kristin Ciombor discuss the treatment implications of the phase 3 PARADIGM trial and other advances in colorectal cancer with guest host and ASCO Daily News Associate Editor, Dr. Shaalan Beg.   TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg, your guest host of the ASCO Daily News Podcast today. I'm an adjunct associate professor at UT Southwestern's Simmons Comprehensive Center and vice president of Oncology at Science 37. I'm delighted to welcome Dr. Aparna Parikh, and Dr. Kristen Ciombor to the podcast today. Dr. Parikh is an assistant professor of Medicine at Harvard University and a GI medical oncologist at the Mass General Hospital Cancer Center. Dr. Ciombor is an associate professor of Medicine and GI medical oncologist at the Vanderbilt University Medical Center. Today, we'll be discussing exciting new approaches using EGFR inhibitors as frontline therapy in colorectal cancer, and promising advances with immune therapy in the treatment of rectal cancer. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found in our transcripts at: asco.org/podcasts. Dr. Parikh, and Dr. Ciombor, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much. Dr. Kristen Ciombor: Thanks so much for having us. Dr. Shaalan Beg: We've seen some exciting advances in GI oncology this year. Let's start with colorectal cancer. Dr. Parikh, there have been many trials looking to compare EGFR and VEGF inhibitors in colorectal cancer. We've heard about the IDEA studies, the FIRE trials, and CALGB 80405. At the 2022 ASCO Annual Meeting, we heard the results of the PARADIGM trial. Have we finally answered the question of when to use EGFR inhibitors as frontline therapy for colorectal cancer? Dr. Aparna Parikh: Thanks so much, Dr. Beg, for this great question. It has been a really exciting year for colorectal cancer across the board. So, the anti-EGFR story is really interesting and has evolved. And maybe just for a little bit of background, we know that colorectal cancer originating from both the right and left side of the colon differ. So, they differ embryologically, and epidemiologically; there are different genetic and molecular aspects to right and left sides of colon cancers. And we have learned over time that in the era of targeted therapy, the primary tumor location has been found to play a very important role, not only in the prognosis of patients but to predict treatment response. We know that patients that have left-sided colon cancers-- and when we think about left-sided colon cancers, we think about cancers that originate from the splenic flexure and descending colon, sigmoid colon, rectosigmoid junction, and sometimes include the rectum in this as well. The rectals have slightly different molecular features than distal colons. And we know that these left-sided patients, overall, have better survival benefits than patients that have right-sided CRC. And that includes again, cecum, ascending colon, hepatic flexure, and transverse colon. So, we know that that had prognostic implications, but what about the predictive implications? And with ASCO, we saw some really exciting data with the PARADIGM study, as Dr. Beg highlighted. We have seen many examples in the past showing the predictive power of anti-EGFR therapy, and anti-EGFR therapy showing a detriment for patients on the right side of the colon. But all these results historically have been obtained by retrospective analysis. So, retrospective analysis of the pivotal CALGB 80405 study, which is the first-line biologic trial. FIRE-3, which is a similar study, but done out of Europe, and KRYSTAL. So all these studies show the same finding but were all obtained basically by retrospective analysis. And what we saw with PARADIGM this year, which is exciting to see, is that this was the first prospective trial to test the superiority of an anti-EGFR inhibitor panitumumab versus bevacizumab in combination with standard doublet first-line chemotherapy for patients that were RAS-wild type. I guess I forgot to mention that again, anti-EGFR therapies are only eligible for patients that are RAS-wild type. We know that RAS-mutant patients and RAS, KRAS HRAS patients don't respond to anti-EGFR therapy. So, the study was looking at RAS-wild type patients, and again, asking the question “was panitumumab better than bevacizumab in combination with chemotherapy for these RAS-wild type patients and for left-sided tumors?” It was a multicenter trial done in Japan-- and I always commend the Japanese on their work and their designs and ability to do these studies that ask really important questions. And, overall survival was the primary endpoint of the study in patients with left-sided tumors, but they also did a full set analysis including patients that didn't have left-sided tumors. They had 823 randomized patients. Many patients, a handful did not receive per-protocol treatment, and some were excluded for other reasons relating to inclusion criteria. And they had 400 patients that ultimately received panitumumab and 402 patients that received bevacizumab in the full set analysis. And of those patients, there were 312 and 292 respectively had left-sided tumors. And although the PFS was comparable between the treatment group, we saw that panitumumab in the left-sided patients actually did improve the OS in both patient populations. But when you looked at the left-sided tumors, the difference was 37.9 versus 34.3 months meeting statistical significance. So, this was an exciting study because it confirmed prospectively what we have seen time and time again, and really behooves us to do early biomarker testing and know RAS status early for these patients with right-sided tumors, as they do derive benefit from anti-EGFR. Maybe I'll just pause there and open it up for more questions or comments from Dr. Ciombor as well. Dr. Kristen Ciombor: Yeah, Dr. Parikh, I thought these data were encouraging. And as you mentioned, the first prospective data that we have in this setting now that we know this primary tumor sidedness matters. Just on a practical note, what do you do in practice? Do you give a lot of anti-EGFR in the first-line? I find that the toxicity can be challenging sometimes and patients may not want to do that. So, it leaves us in a quandary sometimes. Dr. Aparna Parikh: Yeah. So, what's interesting and I don't think we have this data clearly answered yet is, I had, especially for kind of a fit patient-- with the previous data that we've seen with TRIBE and others showing a survival benefit with triplet chemotherapy for first-line therapy, my inclination had actually been to prefer triplet-- and we know that triplet and anti-EGFR toxicity-wise is really, really tough to manage, and really no benefit there that we've seen with OS or PFS, even though you maybe do get a little bit of a better response rate with that. And so where I have sort of struggled is triplet versus just doing first-line doublet plus anti-EGFR. You know, we are not having a discussion about triplet today, but we also saw some data at ASCO showing that perhaps the benefit of the triplet, with the triplet study, is not as much as we had hoped it would've been too. So, it's a good question. I do tend to prefer triplet, I guess, overall, for the healthy, good performance status patient. And then, if not, then doublet. And we, unfortunately, don't have kind of rapid EGFR testing, we're pushing for that. In practice, I think having RAS/RAF status up front would be entirely helpful. It's lumped into our pan-tumor profiling, comprehensive genomic panels. We get microsatellite instability (MSI) status, which I know we'll talk about here next right away. But I think another reason that oftentimes we don't add it right away, is because we don't have the RAS status right away. So, you just start with a doublet and you may end up sneaking it on later. And then, I'd love to, maybe in another podcast, where we can discuss second-line anti-EGFR therapies and what people do in practice for those right-sided patients should they never get anti-EGFR and later-lines of therapy too. And I would argue, perhaps not, because we do see some patients that do benefit, but it can be challenging sometimes with a fresh new patient to make these decisions. But at least, feel encouraged that we're doing the right thing by adding anti-EGFR therapy if they can tolerate it for the left-sided RAS-wild type patient. How about you? What do you do? Dr. Kristen Ciombor: Yeah. Largely, it's a great question. And I don't love giving anti-EGFR therapy. We have an additional issue where I am geographically in that we don't ever give cetuximab because of the high rates of an infusion reaction. So, we pretty much stick to panitumumab and are glad to have that option. But I have started to talk to patients about toxicity and I'm really upfront with the survival data. And it's interesting how people choose differently in terms of what's important to them. And whereas a few extra months in the overall survival may be overshadowed by the toxicity that they have to go through to accomplish that. So, it's good to have many options though, and that's the important thing, and I think the takeaway, as well. Dr. Shaalan Beg: So, kind of brings it back to the fundamentals of practicing medicine, right? Bringing our patients and giving them the options that are most available to them. But I'm going to ask both of you one by one: So, if we have our patient with left-sided colorectal cancer, known as KRAS RAS-wild type, do you recommend EGFR therapy and VEGF therapy and allow the patients to decide, or do you feel that we decide if their profile is such that we should continue with VEGF therapy instead? Dr. Ciombor, do you want to go first? Dr. Kristen Ciombor: Yeah, I think both are good options. I don't only do bevacizumab in the first-line by any means because we do have that survival data. It mostly comes down to a discussion with the patient in terms of toxicities and survival and how well those balance out. Dr. Aparna Parikh: Yeah, very similar. I think we have also gotten a little bit more adept at managing toxicity. I'm pretty aggressive about prophylaxis with even doxy and topicals for managing the rash. And so, for some of my younger patients who are wanting to be "aggressive" and want the exposure to anti-EGFR early but are still very mindful of how it's impacting their day-to-day semblance of self, especially for the younger patients, try to be very proactive about side effect management. And then, of course, we have the patients that have the electrolyte wasting and things too that sometimes if it's bad, we are stuck with infusions frequently and you may end up dropping for those patients. But I think the rash at least I feel like for most patients we can manage if you're aggressive about it too. And I think we have gotten better at that than we were many years ago. Dr. Kristen Ciombor: Never thought we'd be dermatologists, did we? In training, that was definitely not a path I was good at. Dr. Shaalan Beg: Dermato-Oncology, rapidly growing field. So, Dr. Ciombor, the rectal cancer space has evolved very rapidly in recent years, especially when we hear about total neoadjuvant therapy, short-course radiation, watch-and-wait, for those with complete clinical responses. So at ASCO this year, we heard results on immune therapy and rectal cancer. Can you summarize where we are with immune therapy and rectal cancer? Dr. Kristen Ciombor: So, yes. We heard a lot this year at ASCO; both at ASCO GI and ASCO, from the Memorial group and Dr. Cercek's group. And this has been a really exciting advance that we're starting to see and potentially paradigm-shifting data. So, we know-- as you mentioned, that our treatment of rectal cancer, specifically, locally advanced rectal cancer has changed a lot in the last few years with a shift to more Total Neoadjuvant Therapy. And what the Memorial data showed was that for the patients who have microsatellite instability or mismatch repair deficiency, which admittedly, is a small group, but certainly ones that we see in clinic, those patients, on their trial were treated with six months of dostarlimab as neoadjuvant therapy prior to any other treatment; before radiation, surgery, et cetera, and no chemotherapy. And what they found was that actually, six months of dostarlimab in the first 14 evaluable patients actually induced a 100% clinical complete response rate. So, it's really unheard of in most of our trials to see 100%. And I think that caught everyone's attention for sure. I think we have to keep in mind who these patients were and are because they are currently being followed. So, for instance, these were patients that had pretty bulky node-positive disease, almost all these patients did. These were not really early-stage tumors. We did see that 100% were BRAF-wild type, so it does tell us maybe this is not completely the population that we're all seeing when we do see microsatellite instability since we see a lot of sporadic tumors with BRAF mutations. But on the whole, I mean, these were all MSI-high patients and treated with dostarlimab; the six months, that was the total amount of treatment that they received, though a few patients achieved that clinical complete response earlier at about three months, at the three-month reassessment. And what the clinical complete response rate was, was looking both radiographically, as well as endoscopically, and not seeing any sign of residual tumor. I think the important thing here is that median follow-up is still pretty short. There are a few patients who are approaching now two years past that dostarlimab therapy and have not had tumor recurrence, but overall, the median follow-up is still quite short. So, I think we do need to continue to follow these patients. We don't have overall survival data yet either. I think we still have a lot to learn, but this is a very encouraging start and certainly, something that could be really treatment-changing for these patients, which again, as Dr. Parikh was saying, we need this molecular profiling early to make treatment decisions right off the bat, not even only for metastatic now, but even for these locally-advanced rectal cancer patients. Because if you think about it, we've all taken care of patients who have to go through chemoradiation, and chemo, and surgery, and have a lot of morbidity from those treatments so that even if you cure them, they're left with a lot of toxicity. So, if we could avoid some of that, even potentially, surgery, that would be wonderful. But I do caution that this is not the standard of care yet. This is only based on 14 patients with short follow-ups at the current time. But the trial is ongoing, and there are other trials open in this space for patients who don't live in New York or can't get to New York. And for instance, ECOG-ACRIN study 2201 is treating these same patients with nivo and ipi, as opposed to dostarlimab. And that trial is open in about 80 sites now across the US. So hopefully, geographically near all of these patients. Dr. Shaalan Beg: I think a lot of us and a lot of our listeners, that Monday after the results were announced on ASCO had our phone lines and our patient secure messaging lines blowing up. Dr. Kristen Ciombor: We should have warned our nurses and our treatment teams that they would be fielding these questions, yes. On one hand, it's wonderful that our data and the science is getting out to patients. But I think we also have to be really careful as to what is reaching them because many of them didn't realize it was for this subset of patient populations. But great that they're asking those questions and wondering-- being advocates for themselves too. Dr. Shaalan Beg: You use the term clinical complete response. Can you talk about how we determine someone has a complete clinical response and what their follow-up looks like? Dr. Kristen Ciombor: Yeah. In the context of this study, it was actually, as I mentioned, it was both radiographic complete response, as well as endoscopic. So that's one thing that is a little bit tricky when you think about surveillance of these patients. So, it requires a lot, both in frequent surveillance, MRIs, FLEX SIGs often, digital rectal exams, sometimes doing PET scans or CTs, and patients who-- not only on this kind of study but also in non-operative management; watch-and-wait - really have to commit to very close, very frequent follow-up because if the cancer recurs, we don't want to miss that and lose our chance to cure them. So I think that's a little bit different everywhere, how that watch-and-wait approach really manifests, but I think we're learning how to do that, and working in a multidisciplinary group to make sure that patients get the surveillance that they need. Dr. Aparna Parikh: Yeah. I totally agree. If we offer, for the MSI-high patients, if we ultimately end up offering neoadjuvant immunotherapy-- and actually, I'm looking forward to your study, Dr. Ciombor, too, I think the monotherapy versus doublet, too, is going to come up for these patients. But I had a patient just a week or two ago that was starting on this approach with neoadjuvant immunotherapy, but for now, as a group, if we're proceeding down that and they do get a clinical complete response, we're deciding to forego even the radiation and surgery. We're following what they did in the OPRA study, which was pretty aggressive surveillance on the backend, both with direct visualization and MRIs, and you're seeing these patients every three months or so. Dr. Shaalan Beg: Well, thank you Dr. Ciombor and Dr. Parikh for sharing some valuable insights with us on the podcast today. Dr. Aparna Parikh: Thanks so much for having us. It was a lot of fun. Dr. Kristen Ciombor: Thanks for having us on. Dr. Shaalan Beg: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Kristen Ciombor @KristenCiombor Dr. Aparna Parikh @aparna1024   Dr. Shaalan Beg @ShaalanBeg Listen to additional episodes on advances in GI oncology: Novel Therapies in GI Oncology at ASCO22 ASCO22: Key Posters on Advances in GI Oncology Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals Dr. Kristen Ciombor: Consulting or Advisory Role: Merck, Pfizer, Lilly, Seagen, Replimune, Personalis Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi Recipient, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calithera, Genentech, Seagen Travel, Accommodations, Expenses Company: Array Dr. Aparna Parikh: Stock and Ownership Interests: C2i genomics Consulting or Advisory Role: Eli Lilly, Natera, Checkmate Pharmaceuticals, Pfizer, Roche/Genentech, Inivata, Biofidelity, Guardant Health Research Funding(Inst.): PMV Pharma, Plexxikon, Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo

Are you a small business owner that is stuck in the weeds and cant quite get into the flow?  Does your business Yo Yo up and down, without any consistency?   Well our guest today can help.  He is the author of “Strategy Sprints” helping business owners sales soar please welcome Simon Severino to IMPACT. If you like what we are doing please like, share and subscribe to IMPACT This Episode is sponsored by: Todd Palmer's #1 international best selling book From Suck to Success, a guide to extraordinary entrepreneurship. Simon Severino helps business owners in SaaS and Services run their company more effectively which results in sales that soar. Trusted by Google, Roche, Consilience Ventures, Amgen, AbbVie. He created the Strategy Sprints™ Method that doubles revenue in 90  days by getting owners out of the weeds. TEDx speaker, Contributor to Forbes and Entrepreneur Magazine, member of the SVBS Silicon Valley Blockchain Society. Topics: https://www.strategysprints.com/speaking Weblinks  https://www.strategysprints.com/  https://www.facebook.com/strategysprints/  https://twitter.com/strategysprints  https://www.instagram.com/strategysprints/  https://www.linkedin.com/in/simonseverino/  https://www.youtube.com/channel/UCnSFgJd0CrsEdQdO21txR2A  https://podcasts.apple.com/us/podcast/strategy-sprints/id1299008831  https://www.amazon.com/Strategy-Sprints-Accelerate-Growth-Business/dp/139860349X      #entrepreneurship #strategysprints #get control #service #venturecapital #simonseverino #entrepreneursorganization #impact #impactpodcast       

With advances in genetics and other human data, researchers and doctors will one day be able to practice precision medicine. However, predicting how a patient will respond to a medicine is challenging in under-represented patients who are often not included in clinical trials. This is due in part to systemic issues that deter people from participating in research, especially those who have been historically excluded due to factors such as race, ethnicity, sex, and age. In this episode, we talk to Ponda Motsepe-Ditshego, vice president and Global Medical Therapeutic Area head in General Medicine at Amgen, about the recognized differences in disease incidence among racial and ethnic groups and new approaches to increase representation in clinical trials.  To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.   Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.

Biopharma executives and investors are bracing for the impact of the newly passed Inflation Reduction Act. On the latest BioCentury This Week podcast, BioCentury's editors discuss pharma CEOs' warnings that the law will reduce incentives for small molecule drug development, how biotech VCs may adjust deployment of their funds and how the government could implement the law.Turning to readouts from the European Society of Medical Oncology Congress, the BioCentury podcast team explains why the latest data for Amgen's Lumakras could shake up the KRAS inhibitor race and how Chinese investigator-initiated trials are accelerating CAR T innovation.

COVID Diez personas que no tenían sus vacunas al día entre las 12 muertes reportadas por Salud. Hay sobre 1,200 casos reportados por Salud en el día de hoy https://www.metro.pr/noticias/2022/09/13/diez-personas-que-no-tenian-sus-vacunas-al-dia-entre-las-12-muertes-reportadas-por-salud/ Salud eliminará requisito de las mascarillas en las escuelas de P. R. “No significa que porque el gobierno flexibilice no significa que se ha acabado el COVID”, dijo Carlos Mellado, secretario de Salud. https://www.metro.pr/noticias/2022/09/13/salud-eliminara-requisito-de-las-mascarillas-en-las-escuelas-de-p-r/ Salud solicita fondos para atender la viruela símica https://www.elvocero.com/gobierno/agencias/salud-solicita-fondos-para-atender-la-viruela-s-mica/article_56615832-3242-11ed-8742-c7ebb18ebcdf.html Limpieza Internacional de Playa Irma Ruiz Presidenta de la Junta de Directores de Scuba Dogs Society https://scubadogssociety.org/ • Scuba Dogs Society es una organización 501(c)3 sin fines de lucro que se dedica a la protección ambiental en Puerto Rico desde el año 1993, cuando se le conocía como Fundación Enrique Martí Coll. En el 2007, se introdujo su actual nombre. Ha sido puntual para lograr cambios de comportamiento social sobre la protección de los recursos mediante proyectos como la Limpieza Internacional de Costas. A través de la acción, educa y compromete a la comunidad para conservar los recursos naturales limpios y saludables. o www.scubadogssociety.org o https://satc17.scubadogssociety.org/legado-quique/ San Juan, Puerto Rico (lunes, 12 de septiembre de 2022) – Miles de voluntarios convocados por la organización sin fines de lucro Scuba Dogs Society (SDS), organizadora oficial de la Limpieza Internacional de Costas en este país caribeño, harán historia el sábado al completar dos décadas ininterrumpidas del evento, a pesar de enfrentar devastadores huracanes, terremotos, sequías y una pandemia. La presidenta de la Junta de Directores de SDS, Irma “Mimi” Ruiz destacó la magnitud del logro de una comunidad comprometida con el ambiente, que por 20 años ha respondido a la convocatoria de Scuba Dogs Society para encaminar cambios hacia una cultura de reducir y reusar que promueva la armonía con la naturaleza. “Todos en Puerto Rico debemos sentirnos orgullosos por el hito que se marcará este sábado. Es evidencia clara de lo que nos define como pueblo, de lo capaces que somos de unirnos por el amor que sentimos por nuestros recursos y por nuestra gente”, apuntó Ruiz. Resaltó que ha sido clave la participación multisectorial compuesta por la fuerza del voluntariado, organizaciones aliadas, el compromiso de las empresas y sobre todo el liderato de las capitanas y los capitanes de costas. “Este sábado vamos a limpiar 200 costas y áreas naturales a lo largo de Puerto Rico uniéndonos a más de 100 países bajo la iniciativa de Ocean Conservancy. Destacamos la importancia de inscribirse en www.scubadogssociety.org para tener registro de la participación a nivel internacional”, expresó Ruiz. Datos estadísticos de 19 años de la Limpieza Internacional de Costas Ana Trujillo, pasada directora ejecutiva y gerente de proyectos de SDS, indicó que la participación de los ciudadanos ha sido clave en la generación de la base de datos de desperdicios removidos en los cuerpos de agua de Puerto Rico. “Son 19 años de ciencia ciudadana ininterrumpida”, puntualizó. Del análisis de los datos resalta que: • en 11 de los 19 años, Puerto Rico ha estado entre los primeros 20 países con mayor participación de voluntarios y en la mayoría de las ocasiones el número uno a nivel per cápita. • la cifra de voluntarios aumenta mientras el peso de los desperdicios removidos disminuye. Del año 2002 al 2021 han participado 182,370 voluntarios y se han removido casi 3 millones de libras de desechos (2,901,221.36) (ver tabla adjunto) • el peso promedio de la basura por voluntario ha disminuido gradualmente hasta llegar al nivel más bajo de 9.98 libras por voluntario, en el 2021. • Entre el 2008 y el 2021 se ha integrado a 71 municipios que han participado en la Limpieza Internacional de Costas, 37 de ellos por más de 10 años • se ha identificado con datos fehacientes que de los 15 desperdicios más frecuentes removidos entre 2008 y 2021, 11 provienen de los plásticos, aunque históricamente las colillas de cigarrillos han sido el más común. “No existe mejor educación que a través de la acción. Movilizar a todos los segmentos de la comunidad puertorriqueña consistentemente por 20 años seguidos ha logrado una transformación real de comportamiento que hemos podido evidenciar con datos como estos. Aún falta, por supuesto, pero hoy nos corresponde celebrar este gran logro a favor de nuestra convivencia en armonía con la naturaleza”, afirmó, por su parte, Alberto Martí, cofundador de SDS e integrante de la Junta de Directores. Mensaje de Ocean Conservancy: “Ocean Conservancy se complace en celebrar los 20 años de la International Coastal Cleanup (ICC) en alianza con Scuba Dogs Society en Puerto Rico”, dijo Nick Mallos, vicepresidente de plásticos oceánicos de Ocean Conservancy. “La ICC simplemente no sería posible sin el trabajo de cientos de increíbles organizaciones asociadas en todo el mundo que organizan limpiezas locales y recopilan datos. Desde 1986, el ICC ha movilizado a más de 17 millones de voluntarios para eliminar casi 350 millones de libras de basura de las playas y vías fluviales de todo el mundo; y socios firmes como Scuba Dogs Society son una gran parte de este éxito. Esperamos otros 20 años de limpieza y comunidad”. ¿Cómo registrarse? Ruiz recalcó que aún hay áreas que cuentan con capitanes, pero necesitan voluntarios para la limpieza. Exhortó a individuos, familias y grupos a visitar www.scubadogssociety.org para registrarse. Para más información, pueden comunicarse al centro de llamadas de Fondos Unidos: 2-1-1 o acudir a uno de los dos Centros de la Comunidad que ubican en el primer nivel de Plaza Las Américas, antiguo local de First Bank (frente a Red Lobster), en San Juan, y en Plaza del Caribe, en Ponce. El horario de operación será lunes a sábado de 10:00 AM a 8:00 PM. Quienes no puedan asistir a alguna de las limpiezas, también pueden sumarse al #VeinteTú adquiriendo la camiseta conmemorativa del evento en los Centros de la Comunidad y enviando sus donativos a través de ATH Móvil/scubadogssociety o PayPal. La Limpieza Internacional de Costas (#ICC2022) cuenta con el auspicio de: Access All Services, AMGEN, Banco Popular, Bio Strong, Coca-Cola, Colgate-Palmolive Puerto Rico, Compañía de Turismo de Puerto Rico, Cooperativa de Seguros Múltiples, Cummins, Destilería Serrallés, DDB Latina, DRNA, Ecoeléctrica, Econo, El Nuevo Día, First Bank, Fundación Liberty, Magic 97.3, Medtronic, Mc Donald's, Motorambar – KIA, Ocean Conservancy, Para La Naturaleza, Plaza Del Caribe, Plaza Las Américas, Scuba Dogs, T-Mobile y United Way PR, y la colaboración de Fairmont El San Juan Hotel, Gustos Coffee, Lab Warehouse, Unidad de Vectores. Violencia de Género, una perspectiva sociopersonal en El Candil Profesor Edwin Cruz Díaz • Colectivo Ideologías y Vivencias de los Géneros

Did you know PsA and fibromyalgia can coexist? Knowing whether it's fibromyalgia, PsA or both can impact your treatment options. Listen as rheumatologist Dr. Evan Siegel from Arthritis and Rheumatism Associates in Rockville, MD, discusses symptoms, similarities, differences and treatment options. This Psound Bytes episode is provided with support from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Lilly and Pfizer. 

This week on the podcast Agustin discusses news around Amgen's big 1L data drop for its KRAS inhibitor Lumakras, the shifting perceptions for $AMLX and what could become an approval for their ALS therapy, and the shortsightedness of the FDA and CDC around approving covid boosters based only on mouse data!If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

Our guest on the podcast this week is Simon Severino, CEO of Strategy Sprints and Host of the Strategy Sprints podcast. He has interviewed powerhouse entrepreneurs like Rita McGrath, David Allen, Nir Eyal, Perry Marshall, Verne Harnish, Brian Kurtz, and hundreds more on business, productivity, and growth. He helps business owners in SaaS and Services run their companies more effectively which results in sales that soar. He created the Strategy Sprints™ Method that doubles revenue in 90 days by getting owners out of the weeds. Simon leads a global team of Certified Strategy Sprints™ Coaches that help clients gain market share and work in weekly sprints which results in fast execution. His team is trusted by Google, Consilience Ventures, Roche, Amgen, AbbVie, and hundreds of frontier teams. He is a TEDx speaker and has appeared on over 500 podcasts. He writes for Forbes and Entrepreneur Magazine about scaling digital businesses. Today Simon talks about his passion for ‘aliveness' in business, how important our energy is to how we show up to our work, and how creating sacred space is the key to winning teams. As he says, twenty years ago he fell in love with business, how we can start and enter the market, and how to win in business, whatever your interpretation of that is. Although he is undoubtedly a systems guy, he talks freely about energy and the frequency of potential and vibration - how a business needs to inspire people to feel more alive and how his simple methods get incredible results for his clients. Listen in as Simon shares some important yet simple perspectives on how you as a changemaker can fulfill your potential in business while also enjoying the journey and having a life. We discuss the ‘sacred' and how the best performing teams create sacred space, how words have energy, and the potential to shift people's mindsets when you use the correct ways to connect to people's emotions. And I loved it when Simon took a stand against using words like “leads' as he says they are not leads they are interested people so don't dehumanize them in your copy or approach. If you would like some tangible insights about how you can get better at business in ways that will make you feel alive, then I think you will gain some great insights from Simon that will inspire you to perhaps think a little differently about your current approach. I suspect you'll enjoy Simon's unique perspective on the energetic exchange of business and the truth and freedom that is just waiting for you to claim it. I hope you enjoy this conversation as much as I did. Key Takeaways The simple approach to doubling your revenue in just 90 days with strategy sprints How's not about the money, it's about the aliveness What simple steps you can take to grow your business in meaningful ways (and it's not the usual hot air we often hear!) How business is an energetic exchange of understanding, love, and deeply caring for others How to find your ‘sacred' - your way of doing business, your way of selling and marketing so it feels good. Memorable Quote “Most people have a very complicated approach to business and we keep it simple and direct. It's based on 2 very simple things, truth, and freedom. There are just 3 numbers to track, 3 goals, and maximum freedom in how people get there. It's not that hard.” —Simon Severino Episode Resources: http://strategysprints.com/ (Strategy Sprints Website) https://www.linkedin.com/in/simonseverino/ (Simon's Linkedin) http://sacredchangemakers.com/ (SacredChangemakers.com) http://coachesbusinessschool.com/ (CoachesBusinessSchool.com) https://www.instagram.com/jayne_m_warrilow/?hl=en (Jayne Warrilow on Instagram) Thank you to our sponsor: A HUGE thank you to the members of Coaches Business School who are our podcast sponsors, and also our extended community who are helping us to make a global impact aligned with the United Nations Sustainable Development Goals, all visible on our website. If...

Enduring CME will expire on 9/7/2024 Disclosures: Grant/research support: Amarin, Amgen, Boehringer Ingelheim Objectives: 1. To review the cellular and molecular basis of vascular calcification 2. To review population studies of coronary calcification 3. To understand the clinical utility of coronary artery calcification (CAC) testing Accreditation and Designation: The Northeast Georgia Medical Center & Health System, Inc. is accredited by the Medical Association of Georgia to provide continuing medical education for physicians. The Northeast Georgia Medical Center & Health System, Inc. designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Randomized clinical trials are the gold standard for evaluating the efficacy and safety of medicines, but they come with many drawbacks including high monetary and time costs, a lack of representation compared to the general public, and ethical limitations. Historically, these trials were the main mechanism to understand the effects of a medicine. But more recently, real world data from sources such as electronic health records, insurance claims and billing activities, disease registries, and wearable devices, is having a greater effect on understanding a medicine's usage and effects. Although this information is collected outside of clinical trials, clinical researchers incorporate it during the earliest phases of clinical development to gain additional information and speed up the drug development process. In this episode, we talk to Brian Bradbury, vice president of the Center for Observational Research at Amgen, about the increased utilization of real world data and its potential to revolutionize every stage of clinical research, from trial design to regulatory requirements to outcomes measurement. To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.   Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.

On today's episode, Deanna sits down with Will Murphy, Head of Global Diversity, Inclusion, and Belonging (R&D) at Amgen. As the lead of the company's DEI arm, he strives to spearhead a division with a deep commitment to fostering the culture of belonging where diversity is celebrated and inclusion is the norm. Will aims to take on how he leads the segment of a big organization with individuals from all walks of life, and how the company experiences DEI resistance. He will also enlighten how he overcomes these push backs and the synergy between the work and internal segment which plays a big role in his day-to-day operations. TOPICS IN THIS EPISODE What brings Will Murphy Joy Resistance or Push Backs against DEI  Why DEI Resistance Occurs How to Handle Push Backs  Synergizing Business Strategy and Internal Culture Resourcing a Champion at the Organization How to Localize the Strategy RESOURCES: Will's LinkedIn: https://www.linkedin.com/in/wmurphy89/ Will's Twitter: https://twitter.com/wbmurphy89  Deanna's LinkedIn: https://www.linkedin.com/in/deannasingh/  Justin's LinkedIn: https://www.linkedin.com/in/justin-ponder-1200b72b/   Uplifting Impact LinkedIn: https://www.linkedin.com/company/upliftingimpact/  Facebook: https://www.facebook.com/purposefulhustle/?ref=page_internal  Instagram: https://www.instagram.com/deannasingh1/?hl=en  Uplifting Impact YouTube: https://www.youtube.com/channel/UCNs1RS6JqrU7BHeOc5W6SbQ  Uplifting Impact Website: https://www.upliftingimpact.com/?hsLang=en  WHAT'S NEW Uplifting Impact is excited to announce Actions Speak Louder, the latest book by author and DEI expert, our very own, Deanna Singh. This book, available starting May 31st, 2022, is a step-by-step guide on how to create change and inclusivity both in the workplace and beyond. In this book, Deanna seeks to answer questions for organizations and teams of all sizes on how to create more inclusivity. Actions Speak Louder creates a blueprint for those who are ready to read, take action now, and build a better tomorrow. Order Actions Speak Louder NOW: https://www.upliftingimpact.com/actions-speak-louder-book **The Bridge Builder Institute will launch later this year (2022). Launch date to be announced in the near future!** Other Conversations We've Enjoyed The Intersectional Aspect of Greater Inclusion  Diversity, Equity and Inclusion: Digital Equity Learn more about your ad choices. Visit megaphone.fm/adchoices

► About The Guest   Chris Lee is transformational trainer, business/life coach, bestselling author, podcaster star maker, and TV/radio personality from San Juan, Puerto Rico. For 30 years Chris has been traveling the world and has led seminars and workshops that has directly impacted over 1 million people teaching them the art of living abundant, extraordinary, and successful lives. Chris has worked with top companies worldwide such as Dream Works, Google, Paramount Pictures, Universal, Sony Music, WWE, Apple, Microsoft, IBM, Dragados, Amgen, Organifi, among many others.   He also coaches many celebrities and business leaders like Grammy winning recording artist Ednita Nazario, actor Julian Gil, TV anchor Barbara Bermudo, Michelle Wilson (former WWE President), Vanessa Cereseda (President of Ceda), Gabriel Macht (Actor/Director of Suits), Lewis House (School of Greatness) Drew Canoli (Organifi), Bill Glaser (CEO Outstanding Foods), Dave Anderson (Beyond Meat, Outstanding Foods), and many others to create unprecedented results. Lee has been collaborator for top Latin and US television and radio networks like CNN, NBC, ABC, FOX LATINO, Telemundo, Wapa America, Venevision, and Univision. Opened and runs successful seminar businesses in US, Europe, Asia, Latin America, and Puerto Rico. Lee had created a workshop for teens called Torch/Antorcha that teaches adolescents the key to happiness and success lead all over US, Asia, and Latin America.   Lee wrote the best sellers "Dile Yes a la Vida!" and “Transform your life 10 Principles of Abundance and Prosperity" and has been featured in top news and business publications, newspapers such as Huffington Post, Inc Magazine, Success Magazine, Entrepreneur Magazine, Miami Herald, El Nuevo Dia, and Primera Hora.   ► Show Links   https://linktr.ee/liquidityandliquor https://www.instagram.com/chrisleemotivator/   ► Talking Points   00:00 – Intro 00:45 – Meet Chris Lee 10:15 – What determines if someone will make it or not? 15:53 – Chris' book “Transform your life: 10 principles of abundance and prosperity” 33:35 – Importance of coaching 39:30 – Your self-worth is not attached to your image 44:40 – Most people are not present 49:39 – Sourcing and culture 50:28 – How does the law of attraction work? 58:40 – What are the traits that lead to success? 1:09:00 – The importance of your words 1:10:00 – Surround yourself with people that inspires you 1:17:28 – People need to honor themselves 1:19:28 – The values and detriment of the personality types

Simon Severino helps business owners in SaaS and Services run their company more effectively which results in sales that soar. Trusted by Google, Roche, Consilience Ventures, Amgen, AbbVie. He created the Strategy Sprints™ Method that doubles revenue in 90 days by getting owners out of the weeds. TEDx speaker, Contributor to Forbes and Entrepreneur Magazine, member of the SVBS Silicon Valley Blockchain Society. Follow Simon Severino online: https://www.strategysprints.com/ https://www.facebook.com/strategysprints/ https://twitter.com/strategysprints https://www.instagram.com/strategysprints/ https://www.linkedin.com/in/simonseverino/ https://www.youtube.com/channel/UCnSFgJd0CrsEdQdO21txR2A https://podcasts.apple.com/us/podcast/strategy-sprints/id1299008831 https://www.amazon.com/Strategy-Sprints-Accelerate-Growth-Business/dp/139860349X For more information on how you can Own Your Awkward with Andy Vargo, check out https://www.awkwardcareer.com/ #podcast #awkward #ownyourawkward #acceptance #authentiicity #motivation #inspiration #sprint #sales #strategy #b2b #author #investing --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/own-your-awkward/support

Simon Severino helps business owners in SaaS and Services run their companies more effectively resulting in sales that soar. His services are trusted by Google, Roche, Consilience Ventures, Amgen, and AbbVie. He created the Strategy Sprints™ Method that doubles revenue in 90 days by getting owners out of the weeds. He is a TEDx speaker, Contributor to Forbes and Entrepreneur Magazine, and member of the SVBS Silicon Valley Blockchain Society. KEY TAKEAWAYS The key to doubling your company's revenue lies in identifying bottlenecks and solving them. Solving a bottleneck is one of the most important points for achieving this goal, as it will make you energized with motivation! The next thing on our list is habits - creating daily, weekly, or monthly schedules can help us stay organized throughout different parts of life. All these things combined add up to being agile: staying aware enough about what needs doing without wasting time. BEST MOMENTS “There are two reflective questions of all these things. Which one will I delegate tomorrow? And so I review which one gave me energy or took energy from me and which one really moved the whole business forward versus just parts of the business. And the second reflective question is if I would live more freely, and more intentionally, what will I do tomorrow? That's a daily habit. And if everybody does that, in your team, you learn you improve, but also you scale because now everybody starts as soon as they have built something that works.” “If the market breaks down in one week and it takes you three months to change your offers, to change your processes then you are rigid. If it takes you one week to respond on that changing your offers and your processes. Then you're agile.” “Velocity, which means it is speed including the direction of the speed because you can run a marathon and you're the fastest but you're running in the wrong direction. That's the worst thing that can happen to you.” “What's the current bottleneck? So what's the weakest part right now? If we improve that the overall value creation goes higher, more than just if we repair everything a little bit, and so there is always one weak part and that's the bottleneck.” “If you really care about somebody and if you are their advisor, the first part is to really acknowledge their culture and to pick them up at their bus stop, but then get into the next year of the bus and go something, explore a little bit of the wild territory with that bus.” ABOUT THE HOST Levent Yildizgoren, the author of 'Good Business in any Language', is an award-winning entrepreneur, localisation professional, and a PRINCE2 qualified project manager. CONTACT METHOD Linkedin:  https://www.linkedin.com/in/leventyildizgoren/ Twitter: https://twitter.com/yildizgoren IG: https://www.instagram.com/levent.yildizgoren/ ABOUT THE GUEST Simon Severino helps business owners in SaaS and Services run their companies more effectively which results in sales that soar and he is the creator of Strategy Sprints™ Method. CONTACT METHOD https://www.strategysprints.com/ https://www.facebook.com/strategysprints/ https://twitter.com/strategysprints https://www.instagram.com/strategysprints/ https://www.linkedin.com/in/simonseverino/ https://www.youtube.com/channel/UCnSFgJd0CrsEdQdO21txR2A https://podcasts.apple.com/us/podcast/strategy-sprints/id1299008831  https://www.amazon.com/Strategy-Sprints-Accelerate-Growth-Business/dp/139860349X VALUABLE RESOURCES Do you have any questions about translation, localization, or international growth? Visit TTC website: https://ttcwetranslate.com/ Are you curious about how ready you are to go global? Take TTC wetranslate's Scorecard: https://global.scoreapp.com/ Take your business global with the 5-step LINGO modal! Purchase 'Good Business in any Language' on Amazon now: https://cutt.ly/2ORR

Let's understand the business from a company that strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. Chapters:(00:00) Intro (00:16) Business Description(01:05) Industry Landscape(03:22) Annual Financial PerformanceIndustry: Drug Manufacturers—General

JD continues her conversation with Leteria Bailey.  Leteria is a motivated Jamaican-American professional with a passion for serving and advocating for youth and people of color (POC). Through her work serving 5 NGOs in Montgomery County, Maryland, Leteria has researched and developed digital platforms, coordinated public facing organization events, and supported the distribution of over 1.3 million dollars to fund countywide youth development programs. She is currently working with Amgen in Senior Associate Business Communications on their Salesforce Platform.  In 2016 Leteria founded Young Black and Aware to bring national awareness to police brutality and racism in communities of color. Young Black and Aware has garnered international recognition by highlighting social justice issues on a daily basis. As of January 2021, online engagement surpasses 350,000 persons monthly. Notable supporters of Young Black and Aware include American Filmmaker Ava DuVernay, Activist Brittany Packnett-Cunningham, and Artist Bisa Butler.  What You Will Hear: Raising children  Amir Locke https://www.gofundme.com/f/amir-locke-memorial-fund (Go Fund Me) Keeping the memory of those murdered by the police alive Authenticity and mental health Social media What is next for Young, Black and Aware Black censorship on social media What Changing the Narrative means to Leteria Being transparent and authentic Quotes: “The police can kill someone and then the taxpayers pay for it when comes to the settlement.” “I feel like we have a cultural responsibility to come together. We don't have to wait on these schools to do anything, we have the power of the internet, social media. We don't have to wait on these systems to teach us.” “I'm just hoping that in being transparent and authentic, I can inspire other black people to do the same.” Mentioned: Young Black and Awarehttps://www.instagram.com/youngblackandaware/?hl=en ( Instagram) https://www.facebook.com/YoungBlackAndAware/ (facebook)  https://www.tiktok.com/@leteria.keneisha (tik tok)

Få de tre vigtigste pointer fra morgenudsendelsen leveret på mail - bliv medlem på duah.dk, de første 14 dage er gratis. Den planlagte gæstevært måtte desværre melde afbud, men heldigvis kunne vores nye bestyrelsesformand træde til og udfylde rollen i dag. Ring ind til Poul og stil spørgsmål klokken 8.45. Du kan også høre Frank Aaen, Mette Reissmann, Martin Geertsen og meget andet i En Uafhængig Morgen. Tidskoder:  [15:00] : Frank Aaen, næstformand, Statsrevisorerne, statsrevisor. Fhv. MF for Enhedslisten og i dag økonomisk rådgiver ved Enhedslisten // Om danske direktørlønninger er for høje. [29:00] : Mette Reissmann, Medlem af Borgerrepræsentationen i København for Socialdemokratiet // Om Socialdemokratiet bakker ud af valgløfte om at fjerne parkeringspladser i København. [40:00] : Anders Lund Madsen, Journalist, meningsdanner og alt mulig mand (og imod overvågning) // Om mere overvågning skaber mere frihed. [50:00] : Clara Vind og Kristian Henriksen, Journalister på Den Uafhængige // Om det nyeste afsnit af vores nye program “Stoklund-Syndromet”. [01:00:00] : Rasmus Bruun Pedersen, professor på Institut for Statskundskab på Aarhus Universitet // Om den næste kolde krig i Europa er lige om hjørnet. [01:10:00] : Niels Holmark Andersen, overlæge ved Aalborg Universitetshospital // Om det er et problem, at medicinalfirmaer sponsorerer sundhedshøringer på Christiansborg. [01:20:00] : Bjarke Skaaning, Katastrofechef i Røde Kors // Om nogle af verdens store katastrofer bliver glemt i mængden. [01:30:00] : Martin Geertsen, sundhedsordfører for Venstre og vært for medicinalfirmaerne Amgen og Novartis' sundhedshøring // Om folketingspolitikere burde beværte medicinalfirmaers høringer. [01:45:00] : Poul Madsen, Arbejdende bestyrelsesformand på Den Uafhængige // Lytterspørgsmål om Den Uafhængige.

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Joseph Saseen, PharmD, FCCP, FNLA, Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy and Professor, Department of Family Medicine from the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus about managing statin intolerance. Listen in as they discuss how to evaluate statin-associated muscle pain...and review strategies to help patients take a statin successfully. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor HealthAnthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson UniversitySteven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve UniversityJoseph Scherger, MD, MPH, Family Physician, Primary Care 365, Eisenhower HealthCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.Pharmacist's Letter offers CE credit for this podcast. Log in to your Pharmacist's Letter account and look for the title of this podcast in the list of available CE courses.If you're not yet a Pharmacist's Letter subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com. 

Myles Wakeham is an Australian who migrated to the USA in 1989 and has since become a multi-millionaire, lives a 100% free and unconstrained life, not needing a job despite never graduating from high school or college. He is a self-made business focused technologist who was one of the early members of biotechnology corporation Amgen, now the largest Biotech company in the world. An early investor in Bitcoin since 2011, Myles also owns a portfolio of rental properties. In this episode, we highlight the following topics: Why people should throw out the traditional concept of retirement entirely Why do statistics and numbers matter, and what specific statistics represent the greatest threat to personal freedom in the USA? What is "Financial Sustainability"? Why should people get a passport and travel? Why is the wrong sort of debt toxic? Can anyone become financially free in the 21st century, even if they are on a minimum wage? Do you have to have a college education to be successful? Technology, cryptocurrency, and Big Brother Myles Wakeham is Founder of the Financially Independent Contrarian, and can be reached at beunconstrained.com Thank you to our sponsor, CityVest: https://bit.ly/37AOgkp Please check out our affiliate Doc2Doc: doc2doclending.com/financialfreedomforphysicians/ Subscribe to the Premium edition of our podcast and get access to exclusive interviews. Sign up now: anchor.fm/christopher-loo/subscribe

Welcome to Innovating Clinical Trials, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Clinical trials are desperate for innovation. Speed and efficiency need to improve as many patients cannot wait over a decade for new, potentially lifesaving medicines, and trial participants often do not reflect the patient population. Because clinical trials are complex and multidisciplinary, there is not a single, simple solution for accelerating progress. In this series, Rob Lenz, senior vice president of Global Development at Amgen, explores the latest approaches in clinical trial design and execution and highlights real-world examples of how scientists can run trials better and faster to develop optimal medicines that benefit patients.   Our understanding of human biology and disease is progressing at an unprecedented pace, and clinical trial development and execution needs to evolve just as quickly to deliver potentially lifesaving medicines to patients who can't wait. We also need to recruit underrepresented patients into trials, which requires us to think differently about how we identify and recruit patients. In this episode, we talk to Cynthia Verst, president of Design and Delivery Innovation for Research & Development Solutions at IQVIA, a global provider of advanced analytics, technology solutions, and clinical research services. We discuss the drivers for applying innovation in the trial execution space and how the clinical trials model is evolving across the industry thanks to modern innovations. To dive further into this topic, please join Amgen scientists at the Innovating Clinical Trials Q&A webinar discussion on September 28, 2022. Register for the event here.

Leteria Bailey is a motivated Jamaican-American professional with a passion for serving and advocating for youth and people of color (POC). Through her work serving 5 NGOs in Montgomery County, Maryland, Leteria has researched and developed digital platforms, coordinated public facing organization events, and supported the distribution of over 1.3 million dollars to fund countywide youth development programs. She is currently working with Amgen in Senior Associate Business Communications on their Salesforce Platform.  In 2016 Leteria founded Young Black and Aware to bring national awareness to police brutality and racism in communities of color. Young Black and Aware has garnered international recognition by highlighting social justice issues on a daily basis. As of January 2021, online engagement surpasses 350,000 persons monthly. Notable supporters of Young Black and Aware include American Filmmaker Ava DuVernay, Activist Brittany Packnett-Cunningham, and Artist Bisa Butler.  What You Will Hear: Leteria's background and how identifying as a Jamaican-American woman informs who she is. DACA The experience of the  black immigrant  Young, Black and Aware inception and growth Developing a language and validation for processing racial trauma Building community through Young, Black and Aware White people's responsibility in the  deconstruction of white supremacy Quotes: “ if I was motivated by number of followers or number of likes. I would've stopped doing this years ago.” “I can atleast show and speak out about stuff that's going on, if one person is affected, then I've done what I needed to do.” “It's not that young people don't care. It's not that older, black people don't care. It's that not everybody has the emotional bandwidth to take in the impact of that which we deal with on a daily basis. Most of our community is not taught how to process racial trauma.” “ I don't watch black men or women being shot and killed and I'm not gonna share it either. That's just something I can't do anymore. Personally, it's too much.” “ White people are not allies in this struggle.  It is their war and you can't be an ally in a war that you created. The war against white supremacy is their war. This deconstruction has to happen at their hands.” “You love me or you know me and we have relationships with each other, but you see people like me being killed and you don't say anything?” Mentioned Young Black and Awarehttps://www.instagram.com/youngblackandaware/?hl=en ( Instagram) https://www.facebook.com/YoungBlackAndAware/ (facebook)  https://www.tiktok.com/@leteria.keneisha (tik tok) Ava Duvernay 13th When They See Us

Lakshi Aldredge, board-certified Dermatology Nurse Practitioner with the VA Portland Health Care System, answers questions from around the world about skin and scalp psoriasis such as the best soap and moisturizers, over-the-counter sunscreen, hair care products to avoid, what to look for in shampoos and conditioners, and more. This Psound Bytes episode is provided with support from CeraVe, AbbVie, Amgen, Bristol Myers Squibb, Janssen and Lilly. 

Working in a coffee bar means working in close quarters with your fellow baristas, managers, and owners. In this daily work we will eventually begin to feel the tension and start to wonder about how we can set boundaries for ourselves so we can continue to work and still take care of ourselves. The subject of boundaries may be ruminated on but we often do not have a framework to help us organize our values, collect our thoughts, and actually take the first step in communicating with others.  Today I am thrilled to welcome back to the show frequent guest, Tom Henschel, who will guide us through how to accomplish all this and more.  Tom Henschel is an expert in workplace communications and executive development. Over the past 25 years, he has helped hundreds of senior leaders achieve The Look & Sound of Leadership.TM His expertise as a communications coach has taken him into executive offices at companies such as Amgen, CitiGroup, Cedars Sinai Medical Center, City of Hope, Dole, HP, Intuit, Mattel, Raytheon, Sony Pictures, Toyota and Warner Bros. In addition to coaching executives, Tom facilitates team events and delivers highly interactive trainings in the areas of effective communications, presentation, and influence skills. Tom's popular podcast, The Look & Sound of Leadership, airing since 2008, is consistently cited as “What's Hot” in the business podcasts on iTunes. Tom is a delightful persona and deeply wise coach and his insight on boundaries here on KTTS will add a ton of value to you and your buisness.  We cover: What are boundaries? Why do we not set them? The risk of not setting boundaries Spectrum of boundaries Preparing, thoughtfulness, and communicating Self care and weighing options Getting over upsetting others What is our responsibility Corporate vs personal Incremental thinking First steps to take in setting boundaries Links and Resources:  www.essentialcomm.com PDF for setting boundaries   Related Episodes: 052 : Solving Coworker Conflict w/ Tom Henschel 104 : How to Deliver Difficult Feedback w/ Tom Henschel 334 : How to Approach Deescalation w/ Melissa Tucker of Mind Over Matters and Pathways to Peace 221 : Building your People Program w/ HR Consultant Dana Goodwin 165 : The Art of Deep Listening w/ Oscar Trimboli 259 : Solving Toxic Customer Service Culture 258 : Prioritizing your Mental Health in the New Year w/ Dr. Lara Pence Shift Break: The Agreement   Interested in consulting? Click here to schedule a free consulting discovery call with KTTS Click here to book a formal one-on-one consulting call! Visit our amazing Sponsors! www.groundcontrol.coffee www.pacficfoodservice.com www.coffeefest.com

Connie's motivational quote for today is by – Napoleon Hill, “Strength and growth come only through continuous effort and struggle."    As I searched for the right quote to kick off today's show, this one immediately created an image in my mind of the caterpillar struggling out of his cocoon to become the beautiful butterfly that can stretch his wings and fly because of the struggle and effort to tear through the chrysalis.    I know that I and many of my clients keep looking for a quick fix or answer.  In the past 40 years, I have learned that there is no quick fix or magic answer to help us with our business and career growth.  It takes effort like the caterpillar coming out of the chrysalis. So how do we build this business strength so we can continue to fly?   Podcast Super Summit Link:  https://bit.ly/3Qo9YbY  YouTube: https://youtu.be/12fkqDgWSSo   About Simon Severino:   Simon helps business owners in SaaS and Services run their companies more effectively which results in sales that soar. Trusted by Google, Roche, Consilience Ventures, Amgen, and AbbVie. He created the Strategy Sprints™ Method that doubles revenue in 90 days by getting owners out of the weeds. TEDx speaker, Contributor to Forbes and Entrepreneur Magazine, and member of the SVBS Silicon Valley Blockchain Society.   How to Get in Touch With Simon Severino:  Website:  https://www.strategysprints.com/ Email:  severino@strategysprints.com Free Gift Link:  https://bit.ly/3Q8JifT   Stalk me online! LinkTree: https://linktr.ee/conniewhitman Download Free Communication Style Assessment: https://www.changingthesalesgame.com/communication-style-assessment  All-Star Community:  https://changingthesalesgame.mykajabi.com/All-Star-Community   Subscribe and listen to the Changing the Sales Game Podcast on your favorite podcast streaming service or on YouTube.  New episodes post every week - listen to Connie dive into new sales and business topics or problems you may have in your business.

The past year has included the release of new guidelines on cardiovascular disease prevention and further data on cardioprotective agents in type 2 diabetes. In this episode we speak to Prof. Naveed Sattar about these guidelines and how best to help people with type 2 diabetes to reduce their cardiovascular risk. By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References available here Disclosures: Prof. Naveed Sattar declares the following financial relationships from the past 24 months: Advisory - Afimmune, Amgen, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Consulting - Abbott Laboratories, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi Speaker honoraria - Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi Grant funding - AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Efpeglenatide for type 2 diabetes Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

On this episode, we were joined again by Susan Neadle! This episode was focused on the current state of Combination Products globally. Susan and I discuss: - CPC Summit and Updates from FDA - Essential Performance Requirements(EPR's) - ASTM Harmonization for an International  Combination Products Terminology Standard -Different Approaches to Combination Products Globally : US, EU, UK, Canada, Japan, China, Australia, and Saudi Arabia -Upcoming Combination Products Conferences in Q4 Susan Neadle, MS, BS, FAAO is a recognized international Combination Products and Medical Device expert with over 35 years of industry experience.  She is Principal Consultant and President of Combination Products Consulting Services LLC, applying her extensive leadership and technical skills and experience to provide hands-on design-to-value, program management, quality & compliance, and regulatory consulting services, for pharmaceutical, biotech and medical device industries. Among her many significant industry affiliations and contributions, she serves as Chair of the ISPE Combination Products CoP, lead author on the ASTM International Combination Products Standard Committee. Most recently, Susan served as Head of Combination Products, Medical Devices, Digital Health & IVD Regulatory Affairs at Amgen, providing strategic leadership in global combination products/ device regulatory development. Susan retired from Johnson & Johnson. Her distinguished career there of more than 25 years included integral leadership roles in R&D, Quality Engineering, Design-to-Value, Risk Management and Quality Systems, spanning pharmaceuticals, medical devices, and consumer health. She led the team that defined and successfully implemented the globally integrated business model to meet Combination Products regulations for Janssen.

The proposed $5.4 billion takeout of sickle cell company Global Blood Therapeutics by Pfizer is the latest sign of life in biotech M&A, BioCentury Associate Editor Paul Bonanos says on the BioCentury This Week podcast. Bonanos and colleagues explain how Pfizer plans to use its global reach to get Oxbryta to parts of the globe most affected by sickle cell disease, which disproportionately affects people of African, Middle Eastern and South Asian descent. Plus: how schizophrenia data from Karuna makes the biotech ripe for a takeout; amyloidosis data from Alnylam; and why Amgen's latest data for Lumakras suggest the future of one of the most promising KRAS inhibitor combinations is now in doubt.

Curious about the Mediterranean Diet and impact on psoriatic disease? Dr. Adam Ford, UC Davis Health, Dept. of Dermatology and registered dietitian, Danielle Baham, Supportive Oncology & Survivorship, UC Davis Comprehensive Cancer Ctr, discuss evidence supporting use, and how changes lead to improved therapy response and reduce risk of related health conditions. This Psound Bytes episode is provided with support from AbbVie, Amgen, CeraVe, Bristol Myers Squibb, Janssen and Lilly. 

US stocks were mixed Thursday. Plus, Coinbase pops after announcing Blackrock partnership, Amgen is buying ChemoCentryx, and Comcast and Paramount boost streaming.

Hear cardiologist Dr. Nehal Mehta, Chief, Section of Inflammation and Cardiometabolic Diseases at the NIH in Bethesda, MD provide an update on the role "adipokines" play in the development of inflammatory diseases such as psoriasis, along with tips on reducing your inflammatory risk. This Psound Bytes episode is provided with support from AbbVie, Amgen, CeraVe, Bristol Myers Squibb, Janssen and Lilly.

European bourses are firmer across the board, Euro Stoxx 50 +0.9%, with the general tone constructive though the FTSE 100 lags pre-BoE amid GBP strength.US futures have lifted from initial rangebound action, ES +0.3%, with specific newsflow limited pre-data/Fed speak.DXY subdued with peers generally bid though CAD is pressured amid crude consolidation while JPY is the G10 laggard thus far.Core consolidation after recent rampant upward move, knife-edge BoE looms; Bund Sep'22 towards mid-point of a +100 tick range.Currently, benchmarks are firmer by circa. USD 1.00bbl and towards the top-end of relatively/comparably narrow ranges; JCPOA in focusLooking ahead, highlights include US Challenger Layoffs, IJC, International Trade & Canadian Trade Balance, BoE Policy Announcement. Speeches from ECB's Elderson & Fed's Mester. Earnings from Alibaba, Conoco-Phillips, Amgen.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

APAC stocks were firmer as the positive momentum rolled over from global peers (S&P 500 +1.56%, NDX +2.73%)European equity futures are indicative of a higher open with the Euro Stoxx 50 future +0.2% after the cash market closed up 1.3% yesterday.FX markets are relatively contained with the DXY marginally softer, antipodeans outpace peers, GBP steady ahead of BoE. Looking ahead, highlights include EZ & UK Construction PMI, US Challenger Layoffs, IJC, International Trade & Canadian Trade Balance, BoE Policy Announcement, Speeches from ECB's Elderson & Fed's Mester, Supply from Spain & France.Earnings from Cigna, Alibaba, Conoco-Phillips, Amgen, Eli Lilly, Glencore, Rolls-Royce, Adidas, Credit Agricole, Bayer, Lufthansa & Telecom Italia.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Enterprise Knowledge CEO Zach Wahl speaks with Bryan Yee, Director Of Knowledge Management at Amgen, one of the world's largest biotechnology companies. Bryan has been at Amgen for over 16 years and has served as the Director of Knowledge Management since 2019. His team is focused on tapping into the collective genius of drug developers, with a specific focus on fostering a culture of psychological safety and leveraging data science to reduce the friction of knowledge sharing and discovery.

This Episode covers Business Growth, our Guest, is Simon Severino who is based out of Austria.Simon Severino is an Author, CEO of Strategy Sprints, and Host of the Strategy Sprints podcast. His team is trusted by Google, Consilience Ventures, Roche, Amgen, AbbVie, and hundreds of frontier teams.  He is a TEDx speaker, and has appeared on over 500 podcasts. He writes for Forbes and Entrepreneur Magazine about scaling digital businesses.The Business of Business, topics are divided into 4 Categories:  Management, Operations, Sales, and Financial.  Target Audience is Business Owners, C-Level Executives, Management, and anyone considering starting a business.  Helping you run a successful profitable business.

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0659-0000-22-039-H04-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices

Simon Severino helps business owners in SaaS and Services run their company more effectively which results in sales that soar. Trusted by Google, Roche, Consilience Ventures, Amgen, AbbVie. He created the Strategy Sprints™ Method that doubles revenue in 90 days by getting owners out of the weeds. TEDx speaker, Contributor to Forbes and Entrepreneur Magazine, member of the SVBS Silicon Valley Blockchain Society. Links: https://www.amazon.com/Simon-Severino/e/B097BY538K%3Fref=dbs_a_mng_rwt_scns_share https://www.amazon.com/Poems-Night-Rainer-Maria-Rilke/dp/1782275533

Host Melissa Berry had the unique opportunity to speak with Dr. Michele McDermott, Medical Director of Bone Health for Amgen. Dr. McDermott founded the Menopause and Osteoporosis Center in Austin, Texas which she directed until she joined Amgen in 2018.  This episode is packed with tons of information about bone health as it relates to breast cancer. How often should you get a DXA scan? What happens if you don't monitor your bone density during treatment? What are the signs and symptoms of osteoporosis? Tune in to find out her answers to these questions and many more!

Dr. Pamela Kunz, of the Yale Cancer Center, and the JCO consultant editor for Meeting Abstracts, discusses “hidden gems” from ASCO22, highlighting abstracts that address EDI, global health, health care economics, and more. Abstracts/Tweetorials @PamelaKunzMD and @ryangentzler TRANSCRIPT ASCO Daily News: Hello, and welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Pamela Kunz, an associate professor of medicine and director of the Center for Gastrointestinal Cancers at the Yale School of Medicine. Dr. Kunz is also the Journal of Clinical Oncology's (JCO) contributing editor for meeting abstracts. You may have seen her recent tweetorials highlighting compelling abstracts from the 2022 ASCO Annual Meeting. She'll be telling us more about this initiative to highlight impactful studies that address equity, diversity, and inclusion, global oncology, and more. Dr. Kunz's full disclosures are available in the show notes and disclosures relating to all episodes of the podcast can be found on our transcripts at asco.org/podcasts. Dr. Kunz, thanks for being on the podcast today. Dr. Pamela Kunz: Thank you. It's my pleasure to be here. ASCO Daily News: Social media has created a global community in oncology, and you and Dr. Ryan Gentzler of the University of Virginia Cancer Center recently launched a great series of tweetorials to highlight compelling studies from the ASCO Annual Meeting. Some of our listeners will have seen these threads already, and others will be keen to find them and know more about these efforts. Can you give us the details? Dr. Pamela Kunz: Sure, I'd be happy to. This is a new initiative to really modernize the meeting abstracts. These used to be called meeting proceedings and were printed, and we felt that there was a real opportunity to use social media to disseminate more information around abstracts. And we decided this year to focus on four themes. They are diversity, equity, and inclusion; global health; health care economics; and the Merit Award recipients. And within each of these tweetorials, we have 4 to 5 abstracts that are highlighted that include takeaways and a visual from the poster or presentation. We intentionally decided to highlight abstracts that were not otherwise highlighted in the ASCO Annual Meeting in either oral sessions or poster discussions. So we are calling these hidden gems. There are so many great scientific abstracts that don't get otherwise highlighted, and this was a really nice opportunity to do so. ASCO Daily News: Excellent. And I understand you'll be highlighting a couple of abstracts for us today. I believe the first one concerns telehealth used by older patients. Can you tell us about this abstract? Dr. Pamela Kunz: Sure. So this is in the health equity tweetorial, and this is Abstract 1591 by Dr. Higashi and colleagues. And the takeaway from this, I found this interesting, and the disclosure is that I selected these abstracts, given my own personal interests, but I thought that they would be of broad interest to the ASCO membership. So telehealth really became used quite often during COVID, and I think that that has been a real silver lining that there is increased access to expert cancer care through the use of telehealth. This abstract demonstrated that the use of telehealth during cancer treatment was really received positively by older patients, providers, and staff. Most older patients, 66%, and providers and staff, 77%, intended to continue using telehealth after the pandemic. There are certainly some equity issues related to telehealth in terms of access to the internet and the ability to use the technology, but I thought this was interesting because it's specifically focused on older patients. ASCO Daily News: Excellent. Telehealth certainly has been a gamechanger in oncology. I believe the second abstract that you'll be highlighting addresses the use of supportive care in pancreas cancer, correct? Dr. Pamela Kunz: That's exactly right. So this is in the Merit Award tweetorial, and there are so many fantastic Merit Award recipients. It was actually very difficult to select just a few to highlight. In the tweetorial, we will be providing the link to all of the Merit Award recipients. So I encourage listeners to really go look at that. So this specific abstract that I wanted to mention on today's podcast is Abstract 4154 by Dr. Chris Cann and colleagues. They examined, through the National Cancer database, over 150,000 patients with locally advanced pancreatic cancer and found that only 2.9% received supportive care treatment despite over 65% of these patients receiving care at an academic program. And so I think that it just really highlighted the need for these patients to really utilize supportive care programs. Perhaps sometimes we have a bias that we refer patients with metastatic pancreatic cancer to supportive care programs. But there's an opportunity to take advantage of these services earlier. ASCO Daily News: Excellent. Well, Dr. Kunz, looking ahead, do you think there's scope to leverage social media more in oncology? Tweetorials, for example, are a great vehicle for education and a way to address topics that don't get as much attention as we'd like? Dr. Pamela Kunz: Absolutely, Geraldine. You know, this was a pilot this year with Dr. Ryan Gentzler and myself. There is an active social media editor, Dr. Shannon Westin, who's a consultant member of the JCO editorial board as well. I think in partnering with the ASCO Annual Meeting Social Media Team, this has really been a team effort. And we are hoping to do more of this in future years, and in particular, take advantage of creating opportunities for perhaps fellows and junior faculty to assist in disseminating some of this information via social media. ASCO Daily News: Absolutely. This is an incredibly important initiative that will benefit oncologists, patient advocates, and patients alike who are on social media to learn about advances in care. So it's really important that we let our listeners know where they can find these tweetorials. You are on Twitter @PamelKunzMD and Dr. Ryan Gentzler is @ryangentzler. Dr. Kunz, is there anything else you'd like to add before we wrap up the podcast today? Dr. Pamela Kunz: Well, thank you for the opportunity to highlight this. I think we would also welcome suggestions from our listeners. If you are reading the tweetorials, you can send me a direct message, and we'd welcome suggestions for future years on how to highlight other science from our ASCO Annual Meeting. ASCO Daily News: Absolutely. And we'd certainly like to encourage our listeners to share these amazing tweetorials. Well, Dr. Kunz, thanks for coming on the podcast today and for your efforts to elevate abstracts and investigators who are working really hard to address some complex issues in cancer care. Dr. Pamela Kunz: Thank you for the opportunity. ASCO Daily News: And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode, and we'll post the Twitter handles of Dr. Kunz and Dr. Gentzler in the show notes. Finally, if you value the insights you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Show Guest Pamela Kunz, MD Ryan Gentzler, MD Tweetorials: By Pamela Kunz, MD Health Equity/DEI Merit Awards By Ryan Gentzler, MD Cost & Financial Hardship Global Health Disclosures: Dr. Pamela Kunz: Stock and Other Ownership Interests: Guardant Health Consulting or Advisory Role: Ipsen, Lexicon, SunPharma, Acrotech Biopharma, Novartis, Genentech/Roche, Amgen, Crinetics Pharmaceuticals, RayzeBio, Natera, HUTCHMED Research Funding (Inst.): Lexicon, Ipsen, Xencor, Brahms (Thermo Fisher Scientific), Novartis Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

The ability to design proteins to perform desired functions will transform drug development. In particular, with AI and machine learning, scientists gain the ability to engineer antibody-based drugs, including multispecifics which engage multiple targets. By altering existing protein structures or developing proteins de novo, biologics will become more effective and specific. In this episode, we talk to Suzanne Edavettal, the executive director of Protein Engineering at Amgen. We discuss how protein design affects drug development and success rates in the clinic today and in the future. To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.   The Generative Biology Revolution is a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.

Naturally-occurring proteins have evolved over millions of years to perform specific functions based on their sequences and folded structures. As our understanding of science advanced, researchers began designing proteins from scratch to solve new challenges that modern societies face.  In this episode, we talk to David Baker, director of the Institute for Protein Design at the University of Washington and one of the creators of the RoseTTAFold protein structure prediction tool. We discuss how to design proteins with sequences and structures that impart novel functions and how designed proteins will revolutionize drug development. To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.   The Generative Biology Revolution is a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines. Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.

Listen as dermatologist Dr. Laura Ferris, Professor of Dermatology at the University of Pittsburgh, joins us to talk about the primary types of skin cancer, how it compares to psoriasis, risk factors (including those associated with medications), diagnosis, treatments, and steps to protect your skin while in the sun. Psound Bytes is supported by unrestricted educational grants from AbbVie, Amgen, Bristol Myers Squibb and Janssen.